Floatz logo

Tsra-196

Alpha-1 Antitrypsin Deficiency (AATD)

Tessera Therapeutics, Inc.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Alpha-1 Antitrypsin Deficiency (AATD) cohort.

Asset / SponsorPhaseRating
Alpha-1-Proteinase Inhibitor
Grifols Therapeutics LLC
Phase 4A
.ALPHA.-1 PROTEASE INHIBITOR
Grifols Therapeutics LLC
Phase 4A
NORMAL HUMAN SERUM ALBUMIN
Baxalta now part of Shire
Phase 4BBB
.ALPHA.-1 PROTEASE INHIBITOR
Grifols Therapeutics LLC
Phase 3BB
Alpha-1-Proteinase Inhibitor
Grifols Therapeutics LLC
Phase 3BB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →